A double-barrelled, non-surgical treatment could deliver the knock-out punch for a rare type of ovarian cancer.
Granulosa cell tumours of the ovary have a high rate of recurrence and available treatments are nearly always unsuccessful. Now a combination treatment that tackles the body’s defence mechanisms may prove a game-changer.

Highlights Over 90% of granulosa cell tumors have a FOXL2 mutation that contributes to aromatase upregulation. Chemotherapy has demonstrated limited efficacy in the treatment of granulosa cell tumors. A patient with recurrent granulosa cell tumor responded briefly to anastrazole treatment. Retreatment with another aromatase inhibitor letrozole led to a durable response of 24 months. Read Full Article Introduction Granulosa cell tumors (GCTs) represent 3% to 5% of ovarian neoplasms. These tumors arise from the sex-cord stromal cells of the ovary (Colombo et al., 2007). Characteristically, GCTs produce inhibin (Lappöhn et al., 1989) and express aromatase activity promoting estrogen synthesis (Kato et al., 2015). There are two subtypes of GCTs, adult and juvenile, with the former comprising 95% of cases.Most cases of GCT are […]

Patients with recurrent ovarian cancer who received Zejula (niraparib) maintenance therapy experienced more time without symptoms or toxicity compared with placebo, according to results from the phase 3 ENGOT-OV16/NOVA trial. “This TWiST (time without symptoms or toxicity) analysis benefit means that patients treated with niraparib experienced more progression-free time without symptoms or toxicities due to nausea, vomiting, or fatigue compared to placebo,” Ursula A. Matulonis, M.D., director and chief of gynecologic oncology at Dana-Farber Cancer Institute, said during her presentation at the 50th SGO Annual Meeting, held March 16-19 in Honolulu, Hawaii. In the multicenter, double-blind, randomized-controlled trial, patients with […]